Literature DB >> 16021573

alpha(v)beta(3) Integrin in central nervous system tumors.

Michael Lim1, Samira Guccione, Terri Haddix, Leroy Sims, Samuel Cheshier, Pauline Chu, Hannes Vogel, Griffith Harsh.   

Abstract

alpha(v)beta(3) Is an integrin specifically expressed in endothelial cells of newly forming blood vessels. Integrin-mediated angiogenesis is hypothesized to play a central role in the development and the progression of central nervous system neoplasms. Accordingly, it is considered a potential target for antiangiogenic therapy. In the current study, we compare the expression of alpha(v)beta(3) in ependymomas, oligodendrogliomas, pilocytic astrocytomas, medulloblastomas, and vestibular schwannomas (acoustic neuromas). Samples of 5 tumors of each of the 5 tumor types were harvested surgically and frozen. After the pathological diagnosis was confirmed, immunohistochemistry was performed using an anti- alpha(v)beta(3) monoclonal antibody (LM609). The expression of alpha(v)beta(3) was assessed using a 4-tiered (0-3) grading scheme reflecting the percentage of positively staining vessels. All vestibular schwannomas demonstrated strong (grade 3) alpha(v)beta(3) expression. The expression was uniformly prominent in Antoni B regions of the tumors. Of 5 ependymomas, 4 demonstrated uniformly strong alpha(v)beta(3). Oligodendrogliomas, medulloblastomas, and pilocytic astrocytomas demonstrated more variable alpha(v)beta(3). alpha(v)beta(3) may contribute significantly to angiogenesis in vestibular schwannomas and ependymomas. Despite the high vascular density of oligodendrogliomas, pilocytic astrocytomas, and medulloblastomas, these tumors had variable moderate alpha(v)beta(3) expression. This discrepancy suggests temporal and/or regional variability in the angiogenesis in these types of tumor. This study provides the first demonstration of alpha(v)beta(3) expression in vestibular schwannomas, medulloblastomas, and pilocytic astrocytomas.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16021573     DOI: 10.1016/j.humpath.2005.03.014

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  13 in total

1.  Anaplastic glioma.

Authors:  Nina A Paleologos; Ryan T Merrell
Journal:  Curr Treat Options Neurol       Date:  2012-08       Impact factor: 3.598

Review 2.  Targets for therapy in ependymoma.

Authors:  Nicole A Shonka
Journal:  Target Oncol       Date:  2011-03-29       Impact factor: 4.493

Review 3.  Ependymomas in adults.

Authors:  Mark R Gilbert; Roberta Ruda; Riccardo Soffietti
Journal:  Curr Neurol Neurosci Rep       Date:  2010-05       Impact factor: 5.081

4.  Targeting activated integrin alphavbeta3 with patient-derived antibodies impacts late-stage multiorgan metastasis.

Authors:  Karin Staflin; Joseph S Krueger; Janna Hachmann; Jane S Forsyth; Mihaela Lorger; Sebastian C J Steiniger; Jenny Mee; Cristina Pop; Guy S Salvesen; Kim D Janda; Brunhilde Felding-Habermann
Journal:  Clin Exp Metastasis       Date:  2010-03-12       Impact factor: 5.150

5.  Recombinant Integrin β1 Signal Peptide Blocks Gliosis Induced by Aβ Oligomers.

Authors:  Carolina Ortiz-Sanz; Francisco Llavero; Jone Zuazo-Ibarra; Uxue Balantzategi; Tania Quintela-López; Ane Wyssenbach; Estibaliz Capetillo-Zarate; Carlos Matute; Elena Alberdi; José L Zugaza
Journal:  Int J Mol Sci       Date:  2022-05-20       Impact factor: 6.208

6.  Mesenchymal migration as a therapeutic target in glioblastoma.

Authors:  Jessie Zhong; Andre Paul; Stewart J Kellie; Geraldine M O'Neill
Journal:  J Oncol       Date:  2010-06-21       Impact factor: 4.375

7.  The effect of alpha-v integrin inhibition on the malignant characteristics of medulloblastoma.

Authors:  Eric M Thompson; Nathaniel L Whitney; Y Jeffrey Wu; Edward A Neuwelt
Journal:  J Neurosurg Pediatr       Date:  2012-10-19       Impact factor: 2.375

8.  αν and β1 Integrins mediate Aβ-induced neurotoxicity in hippocampal neurons via the FAK signaling pathway.

Authors:  Hai-Yan Han; Jin-Ping Zhang; Su-Qiong Ji; Qi-Ming Liang; Hui-Cong Kang; Rong-Hua Tang; Sui-Qiang Zhu; Zheng Xue
Journal:  PLoS One       Date:  2013-06-03       Impact factor: 3.240

9.  Combination therapy targeting integrins reduces glioblastoma tumor growth through antiangiogenic and direct antitumor activity and leads to activation of the pro-proliferative prolactin pathway.

Authors:  Leticia Oliveira-Ferrer; Jasmin Wellbrock; Udo Bartsch; Eva Maria Murga Penas; Jessica Hauschild; Marianne Klokow; Carsten Bokemeyer; Walter Fiedler; Gunter Schuch
Journal:  Mol Cancer       Date:  2013-11-20       Impact factor: 27.401

10.  Cilengitide induces cellular detachment and apoptosis in endothelial and glioma cells mediated by inhibition of FAK/src/AKT pathway.

Authors:  Leticia Oliveira-Ferrer; Jessica Hauschild; Walter Fiedler; Carsten Bokemeyer; Johannes Nippgen; Ilhan Celik; Gunter Schuch
Journal:  J Exp Clin Cancer Res       Date:  2008-12-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.